Kansas Clinical Trials Report — June 2026

For Kansans considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 45 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 10 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various cardiovascular issues, metabolic conditions, and specific cancers are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Hypertension
• Acute myeloid leukemia (AML)
• Obesity
• Blood pressure regulation
• Adult urological procedures
• Advanced breast cancer
• Adult gynecological procedures
• AML with mutated NPM1
• Adult thoracic procedures
• Atrial fibrillation (AF)

A Surge in New Research Opportunities Across Kansas

This month, Kansas welcomes a notable increase in new clinical trials, with 20 studies opening their doors to participants. This marks a significant rise from the 17 trials that opened in May 2026, indicating a growing landscape for medical innovation in the state. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering Kansans access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring two major Phase 3 trials focused on weight management. NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," is a substantial global study aiming to enroll 3,600 participants. It will investigate the long-term efficacy, safety, and tolerability of aleniglipron. Additionally, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," seeks 1,100 participants to evaluate aleniglipron in individuals with both weight challenges and type 2 diabetes.
• Pfizer is leading an important Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to learn about the safety and effectiveness of a new pneumococcal vaccine in infants, helping to fight against germs that can cause serious infections like pneumonia and meningitis.
• For individuals experiencing migraines, Kallyope Inc. is sponsoring two Phase 3 trials. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targets 1,800 participants to assess the efficacy, safety, and tolerability of elismetrep compared with placebo. A companion study, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will enroll 1,000 participants to evaluate the long-term safety of intermittent use of the same study drug.
• AstraZeneca is also a prominent sponsor this month with two significant Phase 3 trials for type 2 diabetes mellitus. NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," plans for 1,200 participants to compare elecoglipron with an existing treatment. Another AstraZeneca study, NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus," seeks 800 participants to evaluate elecoglipron alone or in combination with dapagliflozin.
• A unique long-term study, NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," sponsored by RTI International, aims to enroll 1,400 participants. This study follows people with Down syndrome of all ages to better understand their health, development, and everyday experiences over time.

Expanding Research for Diverse Health Needs

The 20 new trials opening this month in Kansas cover a diverse range of health conditions, with a strong focus on metabolic health. The most common conditions addressed by these new studies include:

• Obesity
• Overweight
• Type 2 diabetes mellitus
• Chronic weight management
• COVID-19
• Down syndrome
• Graves disease

In terms of intervention types, drug trials lead the way, accounting for 14 of the new studies. Device trials and other types of research, including biological treatments and procedures, also represent new opportunities for participation.

Geographic Reach: Opportunities Across Kansas

Kansas's clinical research landscape is robust, with 853 clinical trials currently recruiting across 44 cities and 448 research sites statewide. This month, new research initiatives are concentrated in the state's major metropolitan areas, ensuring accessibility for many residents. The cities with the most new trials include:

• Kansas City (6 new trials)
• Overland Park (5 new trials)
• Wichita (5 new trials)
• Lenexa (2 new trials)
• Topeka (2 new trials)

Beyond these hubs, smaller cities like Newton, El Dorado, Derby, and Pittsburg each welcomed one new trial, demonstrating a commitment to spreading research opportunities across the state. This distribution ensures that residents in various regions of Kansas have access to cutting-edge research, even as the larger cities remain central to clinical investigations.

Participation: Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 20 new trials launched this month, 4 are actively seeking healthy volunteers. Statewide, a total of 84 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Kansas are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 6 include children as participants, and 14 include older adults, ensuring that research benefits diverse age groups. Industry sponsors are driving the majority of new research efforts, with 16 new trials sponsored by pharmaceutical companies such as AstraZeneca, Gasherbrum Bio, Inc., Kallyope Inc., Eli Lilly and Company, Novo Nordisk A/S, and Pfizer. An additional 4 trials are sponsored by other organizations, including academic institutions and non-profits.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Kansas.